Simcyp, a division of Certara, said this week that it has entered into a Cooperative Research and Development Agreement with the US Food and Drug Administration to further develop the Simcyp Dog model for the evaluation of drug products intended for use in different canine breeds.
Over the next five years, Simcyp and researchers at the FDA's Center for Veterinary Medicine will develop physiologically based pharmacokinetic dog models that will help streamline the process of veterinary drug product development and evaluation.
Simcyp already provides an animal PBPK simulator, based on the Simcyp Population-based Simulator, for the beagle dog, rat, and knock-out mouse.
The partners will apply pharmacokinetic modeling to address complex questions associated with the design and interpretation of target animal safety studies and clinical field studies, Simcyp said.
Furthermore, they will enable the integration of model predictions with data from safety and effectiveness studies to support the development of informative product labels, Simcyp said.
The virtual dog models will provide a way to evaluate different dose requirements while taking into account genetic variations between breeds, Amin Rostami-Hodjegan, Simcyp’s vice president of scientific research and development, noted in a statement.